An ensemble approach (enFoldX) that leverages structure prediction models such as AlphaFold3 to build sensitive binding predictors and outperforms the current co-folding methods which rely on predictions from the single top ranked structure.
O. Lyudovyk, Jonathan A. Levine, M. Pathil et al.· Clinical Cancer Research· 0 citations
An ensemble approach (enFoldX) that leverages structure prediction models such as AlphaFold3 to build sensitive binding predictors and outperforms the current co-folding methods which rely on predictions from the single top ranked structure.
O. Lyudovyk, Jonathan A. Levine, M. Pathil et al.· Clinical Cancer Research· 0 citations
Adaptive immunity relies on T-cell receptor (TCR) recognition of peptides presented by the major histocompatibility complex (pMHC). Accurate prediction of TCR:pMHC binding pairs from sequence data remains a longstanding challenge in computational immunology, limiting the development of precision immunotherapies like cancer vaccines and adoptive cell therapies. Here, we present enFoldX (ensemble of Folded compleXes), a structure-based approach leveraging biophysical characterization of AlphaFold3-generated ensembles to classify TCR:pMHC sequence pairs as cognate versus non-cognate. Unlike previous methods reliant on only sequence data or a single, static predicted structure, enFoldX extracts features from an entire generated ensemble with a custom focus on the biophysical binding interface. Our model distinguishes T cell reactivity between peptides differing by a single amino acid substitution, the resolution required for cancer neoantigens, and generalizes to unseen peptides, MHCs, and TCRs, a major objective for artificial intelligence (AI) in immunology. Our performance on these crucial tasks demonstrates that diverse, structural sampling of biophysical interactions over an ensemble is fundamental for accurate AI-driven binding predictions and offers lessons for efficient future data generation to improve models. Our findings therefore offer a scalable framework to accelerate therapeutic binder design, and we provide access to a publicly available code repository.
O. Lyudovyk, JA Levine, M. Pathil et al.· bioRxiv· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
